Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $25.63

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned a consensus recommendation of “Hold” from the eleven research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $25.6250.

A number of equities analysts recently issued reports on the stock. BTIG Research dropped their price target on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. UBS Group dropped their target price on shares of Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. JMP Securities reduced their price target on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a research report on Monday, September 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Wednesday, October 8th. Finally, Evercore ISI cut their target price on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research note on Monday, September 22nd.

Jasper Therapeutics Stock Performance

Shares of Jasper Therapeutics stock traded up $0.07 during midday trading on Friday, hitting $1.82. The company had a trading volume of 193,106 shares, compared to its average volume of 400,083. Jasper Therapeutics has a 52-week low of $1.56 and a 52-week high of $26.05. The stock has a market capitalization of $50.90 million, a P/E ratio of -0.31 and a beta of 2.83. The company has a 50 day moving average of $2.16 and a 200 day moving average of $3.35.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, November 10th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.12). Equities research analysts forecast that Jasper Therapeutics will post -4.47 EPS for the current year.

Insider Activity at Jasper Therapeutics

In related news, Director Svetlana Lucas acquired 20,000 shares of the firm’s stock in a transaction dated Monday, September 22nd. The stock was purchased at an average cost of $2.43 per share, with a total value of $48,600.00. Following the completion of the acquisition, the director directly owned 20,000 shares of the company’s stock, valued at approximately $48,600. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Judith Anne Shizuru bought 41,000 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was bought at an average price of $2.43 per share, for a total transaction of $99,630.00. Following the acquisition, the director directly owned 156,901 shares of the company’s stock, valued at $381,269.43. The trade was a 35.38% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 143,000 shares of company stock worth $347,490 over the last quarter. 4.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock worth $1,005,000 after acquiring an additional 23,453 shares during the period. Bank of Montreal Can boosted its position in Jasper Therapeutics by 120.4% in the second quarter. Bank of Montreal Can now owns 158,133 shares of the company’s stock worth $878,000 after purchasing an additional 86,393 shares during the last quarter. Nuveen LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $440,000. Kingdon Capital Management L.L.C. increased its position in shares of Jasper Therapeutics by 9.6% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 490,000 shares of the company’s stock valued at $2,107,000 after purchasing an additional 43,000 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its stake in shares of Jasper Therapeutics by 755.3% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 702,757 shares of the company’s stock worth $3,022,000 after purchasing an additional 620,592 shares during the period. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.